Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy

US11167029B2 · kind B2 · utility

Assignee

• AFFIMED GMBH · DE

Inventors

• Martin Treder · Heidelberg, DE
• Uwe Reusch · Maikammer, DE
• Jens-Peter Marschner · Seeheim-Jugenheim, DE
• Stefan Knackmuss · Plankstadt, DE

Key dates

• Filing date: Oct 19, 2017
• Grant date: Nov 9, 2021
• Expiry date: Oct 19, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.